243 related articles for article (PubMed ID: 28372872)
21. Ovarian cancer outcomes: Predictors of early death.
Urban RR; He H; Alfonso R; Hardesty MM; Gray HJ; Goff BA
Gynecol Oncol; 2016 Mar; 140(3):474-80. PubMed ID: 26743531
[TBL] [Abstract][Full Text] [Related]
22. Impact of provider volume on front-line chemotherapy guideline compliance and overall survival in elderly patients with advanced ovarian cancer.
Aviki EM; Lavery JA; Roche KL; Cowan R; Dessources K; Basaran D; Green AK; Aghajanian CA; O'Cearbhaill R; Jewell EL; Leitao MM; Gardner GJ; Abu-Rustum NR; Sabbatini P; Bach PB
Gynecol Oncol; 2020 Nov; 159(2):418-425. PubMed ID: 32814642
[TBL] [Abstract][Full Text] [Related]
23. Statin treatment is associated with survival in a nationally representative population of elderly women with epithelial ovarian cancer.
Vogel TJ; Goodman MT; Li AJ; Jeon CY
Gynecol Oncol; 2017 Aug; 146(2):340-345. PubMed ID: 28596017
[TBL] [Abstract][Full Text] [Related]
24. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV).
Glasgow MA; Yu H; Rutherford TJ; Azodi M; Silasi DA; Santin AD; Schwartz PE
J Surg Oncol; 2013 Feb; 107(2):195-200. PubMed ID: 22648987
[TBL] [Abstract][Full Text] [Related]
25. Digoxin therapy is not associated with improved survival in epithelial ovarian cancer: A SEER-Medicare database analysis.
Vogel TJ; Jeon C; Karlan B; Walsh C
Gynecol Oncol; 2016 Feb; 140(2):285-8. PubMed ID: 26691221
[TBL] [Abstract][Full Text] [Related]
26. Pre-diagnosis health-related quality of life, surgery, and survival in women with advanced epithelial ovarian cancer: A SEER-MHOS study.
Doll KM; Pinheiro LC; Reeve BB
Gynecol Oncol; 2017 Feb; 144(2):348-353. PubMed ID: 27988047
[TBL] [Abstract][Full Text] [Related]
27. Is it possible to define an optimal time for chemotherapy after surgery for ovarian cancer?
Lydiksen L; Jensen-Fangel S; Blaakaer J
Gynecol Oncol; 2014 Jun; 133(3):454-9. PubMed ID: 24726613
[TBL] [Abstract][Full Text] [Related]
28. Socioeconomic status as a predictor of adherence to treatment guidelines for early-stage ovarian cancer.
Hodeib M; Chang J; Liu F; Ziogas A; Dilley S; Randall LM; Anton-Culver H; Bristow RE
Gynecol Oncol; 2015 Jul; 138(1):121-7. PubMed ID: 25913132
[TBL] [Abstract][Full Text] [Related]
29. Variation in neoadjuvant chemotherapy utilization for epithelial ovarian cancer at high volume hospitals in the United States and associated survival.
Barber EL; Dusetzina SB; Stitzenberg KB; Rossi EC; Gehrig PA; Boggess JF; Garrett JM
Gynecol Oncol; 2017 Jun; 145(3):500-507. PubMed ID: 28366545
[TBL] [Abstract][Full Text] [Related]
30. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands.
van Altena AM; Karim-Kos HE; de Vries E; Kruitwagen RF; Massuger LF; Kiemeney LA
Gynecol Oncol; 2012 Jun; 125(3):649-54. PubMed ID: 22370602
[TBL] [Abstract][Full Text] [Related]
31. Ultra-radical upfront surgery does not improve survival in women with advanced epithelial ovarian cancer; a natural experiment in a complete population.
Falconer H; Joneborg U; Krawiec K; Palsdottir K; Bottai M; Salehi S
Gynecol Oncol; 2020 Oct; 159(1):58-65. PubMed ID: 32712154
[TBL] [Abstract][Full Text] [Related]
32. Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center.
Schlappe BA; Mueller JJ; Zivanovic O; Gardner GJ; Long Roche K; Sonoda Y; Chi DS; O'Cearbhaill RE
Gynecol Oncol; 2016 Jul; 142(1):13-18. PubMed ID: 27189456
[TBL] [Abstract][Full Text] [Related]
33. Effect of adoption of neoadjuvant chemotherapy for advanced ovarian cancer on all cause mortality: quasi-experimental study.
Melamed A; Fink G; Wright AA; Keating NL; Gockley AA; Del Carmen MG; Schorge JO; Rauh-Hain JA
BMJ; 2018 Jan; 360():j5463. PubMed ID: 29298771
[TBL] [Abstract][Full Text] [Related]
34. Neoadjuvant chemotherapy is associated with prolonged primary treatment intervals in patients with advanced epithelial ovarian cancer.
Milam MR; Tao X; Coleman RL; Harrell R; Bassett R; Dos Reis R; Ramirez PT
Int J Gynecol Cancer; 2011 Jan; 21(1):66-71. PubMed ID: 21178571
[TBL] [Abstract][Full Text] [Related]
35. Impact of the time interval from completion of neoadjuvant chemotherapy to initiation of postoperative adjuvant chemotherapy on the survival of patients with advanced ovarian cancer.
Lee YJ; Chung YS; Lee JY; Nam EJ; Kim SW; Kim S; Kim YT
Gynecol Oncol; 2018 Jan; 148(1):62-67. PubMed ID: 29174056
[TBL] [Abstract][Full Text] [Related]
36. Centralisation of epithelial ovarian cancer surgery: results on survival from a peripheral teaching hospital.
van Vliet MM; Schreuder HW; Pasker-de Jong PC; Duk MJ
Eur J Obstet Gynecol Reprod Biol; 2015 Sep; 192():72-8. PubMed ID: 26177496
[TBL] [Abstract][Full Text] [Related]
37. Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study.
Olawaiye AB; Java JJ; Krivak TC; Friedlander M; Mutch DG; Glaser G; Geller M; O'Malley DM; Wenham RM; Lee RB; Bodurka DC; Herzog TJ; Bookman MA
Gynecol Oncol; 2018 Oct; 151(1):18-23. PubMed ID: 30135020
[TBL] [Abstract][Full Text] [Related]
38. Fertility preservation and survival among young women with early ovarian cancer living in US counties with gynecologic oncologist services.
Hillman RT; Saenz CC; McHale MT; Plaxe SC
Int J Gynaecol Obstet; 2017 May; 137(2):157-163. PubMed ID: 28170079
[TBL] [Abstract][Full Text] [Related]
39. Effects of access to and treatment in specialist facilities on survival from epithelial ovarian cancer in Australian women: a data linkage study.
Tracey E; Hacker NF; Young J; Armstrong BK
Int J Gynecol Cancer; 2014 Sep; 24(7):1232-40. PubMed ID: 25153678
[TBL] [Abstract][Full Text] [Related]
40. Intraperitoneal chemotherapy among women in the Medicare population with epithelial ovarian cancer.
Fairfield KM; Murray K; LaChance JA; Wierman HR; Earle CC; Trimble EL; Warren JL
Gynecol Oncol; 2014 Sep; 134(3):473-7. PubMed ID: 24952367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
